WO2003068162A3 - Modified fluorinated nucleoside analogues - Google Patents

Modified fluorinated nucleoside analogues Download PDF

Info

Publication number
WO2003068162A3
WO2003068162A3 PCT/US2003/004379 US0304379W WO03068162A3 WO 2003068162 A3 WO2003068162 A3 WO 2003068162A3 US 0304379 W US0304379 W US 0304379W WO 03068162 A3 WO03068162 A3 WO 03068162A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleoside analogues
modified fluorinated
fluorinated nucleoside
flavirius
hepacivirus
Prior art date
Application number
PCT/US2003/004379
Other languages
French (fr)
Other versions
WO2003068162A2 (en
Inventor
Lieven J Stuyver
Jinxing Shi
Kyoichi A Watanabe
Original Assignee
Pharmasset Ltd
Lieven J Stuyver
Jinxing Shi
Kyoichi A Watanabe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd, Lieven J Stuyver, Jinxing Shi, Kyoichi A Watanabe filed Critical Pharmasset Ltd
Priority to CA002476279A priority Critical patent/CA2476279A1/en
Priority to EP03713447A priority patent/EP1480982A4/en
Priority to BR0307712-8A priority patent/BR0307712A/en
Priority to KR10-2004-7012661A priority patent/KR20040094692A/en
Priority to NZ534811A priority patent/NZ534811A/en
Priority to MXPA04007876A priority patent/MXPA04007876A/en
Priority to AU2003217402A priority patent/AU2003217402A1/en
Priority to JP2003567347A priority patent/JP2005522443A/en
Publication of WO2003068162A2 publication Critical patent/WO2003068162A2/en
Publication of WO2003068162A3 publication Critical patent/WO2003068162A3/en
Priority to ZA2004/06858A priority patent/ZA200406858B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

The invention is a compound, composition, use for and a method of treating Flaviviridae (Hepacivirus, Flavirius, Pestivirus) infections, including BVDV and HCV, or abnormal cellular proliferation, including malignant tumors, in a host including animals, and especially humans, using a ß-D or ß-L nucleoside of general formula (1) - (XX), or their pharmaceutically acceptable salt or prodrug thereof.
PCT/US2003/004379 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues WO2003068162A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002476279A CA2476279A1 (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues
EP03713447A EP1480982A4 (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues
BR0307712-8A BR0307712A (en) 2002-02-14 2003-02-13 Compound, composition and use in the treatment of flaviviridae infections and abnormal cell proliferation
KR10-2004-7012661A KR20040094692A (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues
NZ534811A NZ534811A (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues
MXPA04007876A MXPA04007876A (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues.
AU2003217402A AU2003217402A1 (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues
JP2003567347A JP2005522443A (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues
ZA2004/06858A ZA200406858B (en) 2002-02-14 2004-08-27 Modified fluorinated nucleoside analoques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35741102P 2002-02-14 2002-02-14
US60/357,411 2002-02-14
US35814002P 2002-02-20 2002-02-20
US60/358,140 2002-02-20

Publications (2)

Publication Number Publication Date
WO2003068162A2 WO2003068162A2 (en) 2003-08-21
WO2003068162A3 true WO2003068162A3 (en) 2004-03-11

Family

ID=27737594

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/004379 WO2003068162A2 (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues
PCT/US2003/004481 WO2003068164A2 (en) 2002-02-14 2003-02-14 Dosing regimen for gemcitabine hcv therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004481 WO2003068164A2 (en) 2002-02-14 2003-02-14 Dosing regimen for gemcitabine hcv therapy

Country Status (12)

Country Link
US (2) US20040002476A1 (en)
EP (2) EP1480982A4 (en)
JP (2) JP2005522443A (en)
KR (2) KR20040094692A (en)
CN (2) CN1646534A (en)
AU (2) AU2003217402A1 (en)
BR (1) BR0307712A (en)
CA (2) CA2476279A1 (en)
MX (2) MXPA04007876A (en)
NZ (1) NZ534811A (en)
WO (2) WO2003068162A2 (en)
ZA (1) ZA200406858B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186369B2 (en) 2003-07-25 2015-11-17 Idenix Pharmaceuticals, Llc Purine nucleoside analogues for treating flaviviridae including hepatitis C

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414520T1 (en) 2000-04-13 2008-12-15 Pharmasset Inc 3 OR 2 HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND THEIR USE FOR TREATING VIRUS INFECTIONS
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (en) * 2000-05-26 2009-12-02 Idenix (Cayman) Limited Use of nucleoside derivatives for preparation of pharmaceutical compositions for treating infections caused by flaviviruses and pestiviruses
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
BR0312278A (en) * 2002-06-28 2007-06-19 Idenix Cayman Ltd 2'-c-methyl-3'-o-1-valine ribofuranosyl cytidine ester for treatment of flaviviridae infections
CN101172993A (en) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CA2494340C (en) 2002-08-01 2012-01-24 Pharmasset Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
RU2005121904A (en) * 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) METHOD FOR PRODUCING 2`-BRANCHED NUCLEOSIDES
NZ540913A (en) * 2002-12-23 2008-02-29 Idenix Cayman Ltd Process for the production of 3'-nucleoside prodrugs
US20050049204A1 (en) * 2003-03-28 2005-03-03 Otto Michael J. Compounds for the treatment of flaviviridae infections
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
AU2005256963A1 (en) * 2004-06-23 2006-01-05 Centre National De La Recherche Scientifique 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
US7879816B2 (en) * 2005-06-07 2011-02-01 Yale University Methods of treating cancer and other conditions or disease states using LFMAU and LDT
US7951788B2 (en) * 2005-12-02 2011-05-31 Yale University Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
WO2007075876A2 (en) * 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
PL2368882T3 (en) * 2007-09-17 2015-04-30 Abbvie Bahamas Ltd Anti-infective pyrimidines and uses thereof
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20110171192A1 (en) 2008-09-05 2011-07-14 Hiroshi Tomiyama Substituted amine derivative and medicinal composition comprising same as the active ingredient
WO2011156757A1 (en) * 2010-06-10 2011-12-15 Gilead Sciences, Inc. Combination of anti-hcv compounds with ribavirin for the treatment of hcv
CN104884462A (en) * 2012-10-29 2015-09-02 共晶制药股份有限公司 Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
SG11201503750YA (en) 2012-11-16 2015-06-29 Univ Cardiff Process for preparing nucleoside prodrugs
JP2016522172A (en) 2013-04-12 2016-07-28 アキリオン ファーマシューティカルズ，インコーポレーテッド Deuterated nucleoside prodrugs useful for treating HCV
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
EP3618837A4 (en) 2017-04-26 2020-11-04 Thomas I. Kalman Multitargeted nucleoside derivatives
JP2020125245A (en) * 2019-02-01 2020-08-20 ダイキン工業株式会社 Anti-hepatitis C virus agent

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (en) * 1984-12-04 1993-08-15 Lilly Co Eli TUMOR TREATMENT IN MAMMALS.
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
HU204843B (en) * 1988-09-27 1992-02-28 Merrell Dow Pharma Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same
US5616702A (en) * 1988-11-15 1997-04-01 Merrell Pharmaceuticals Inc. 2-'-ethenylidene cytidine, uridine and guanosine derivatives
ZA898567B (en) * 1988-11-15 1990-08-29 Merrell Dow Pharma Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine,uridine and guanosine derivatives
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
TW224053B (en) * 1991-09-13 1994-05-21 Paul B Chretien
KR100258668B1 (en) * 1992-04-10 2000-07-01 슈테펜 엘.네스비트 Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a s-shape or m-phase specific antineoplastic agent
HU217963B (en) * 1992-05-12 2000-05-28 Merrell Dow Pharmaceuticals Inc. Process for the preparation of ribonucleotide reductase inhibitors
YU43193A (en) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-DEOXY-2 ', 2'-DIFLUORO (4-SUBSTITUTED) PYRIMIDINE NUCLEOSIDS OF ANTIVIRUS AND ANTICANCEROGENIC ACTIVITY AND INTERMEDIATES
EP0686043B1 (en) * 1993-02-24 1999-06-23 WANG, Jui, H. Compositions and methods of application of reactive antiviral polymers
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
DE4432623A1 (en) * 1994-09-14 1996-03-21 Huels Chemische Werke Ag Process for bleaching aqueous surfactant solutions
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB9601680D0 (en) * 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5830905A (en) * 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5891874A (en) * 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5922757A (en) * 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
DK1009732T3 (en) * 1997-06-30 2003-09-22 Merz Pharma Gmbh & Co Kgaa 1-Amino-alkylcyclohexane NMDA receptor antagonists
BR9908270A (en) * 1998-02-25 2004-06-29 Univ Emory 2-Fluoro-nucleosides, pharmaceutical compositions and their uses
GB9806815D0 (en) * 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
WO2000021565A1 (en) * 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
EA200200778A1 (en) * 2000-02-18 2003-06-26 Шайре Байокем Инк. METHOD OF TREATMENT OR PREVENTION OF HEPATITIS C INFECTION IN THE ORGANISM ORGANISM, PHARMACEUTICAL COMPOSITION AGAINST FLAVIVIRUS, CONNECTION OF FORMULA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION OF EFFECTECH EFFECTURES Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION INEKEKHEKUSA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PROTECTION
PL365664A1 (en) * 2000-08-02 2005-01-10 Ortho-Mcneil Pharmaceutical, Inc. Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
AU2002303187C1 (en) * 2001-03-30 2008-06-12 Bukwang Pharmaceutical Company Ltd Process for the preparation of 2'-HALO-Beta-L-arabinofuranosyl nucleosides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUANG ET AL.: "Fluorinated sugar analogues of potential anti-hiv-1 nucleosides", J. MED. CHEM., vol. 34, 1991, pages 1640 - 1646, XP002970744 *
MARTIN ET AL.: "Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1)", J. MED. CHEM., vol. 33, 1990, pages 2137 - 2145, XP002970743 *
TOYOTA ET AL.: "Addition of molecular fluorine to 2-azabicyclo(2.2.1)hept-5-en-3-one and related compounds: Synthesis of difluorinated carbocyclic nucleosides", TETRAHEDRON, vol. 52, no. 31, pages 8783 - 8798, XP002063691 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186369B2 (en) 2003-07-25 2015-11-17 Idenix Pharmaceuticals, Llc Purine nucleoside analogues for treating flaviviridae including hepatitis C

Also Published As

Publication number Publication date
BR0307712A (en) 2005-05-24
WO2003068162A2 (en) 2003-08-21
KR20040094692A (en) 2004-11-10
AU2003217414A1 (en) 2003-09-04
CN1646129A (en) 2005-07-27
CA2476282A1 (en) 2003-08-21
MXPA04007878A (en) 2005-06-20
AU2003217402A1 (en) 2003-09-04
ZA200406858B (en) 2005-09-28
EP1480982A2 (en) 2004-12-01
US20030225029A1 (en) 2003-12-04
EP1482943A2 (en) 2004-12-08
NZ534811A (en) 2007-07-27
US20040002476A1 (en) 2004-01-01
JP2005522443A (en) 2005-07-28
WO2003068164A2 (en) 2003-08-21
WO2003068164A3 (en) 2004-03-11
AU2003217414A8 (en) 2003-09-04
KR20040091052A (en) 2004-10-27
EP1480982A4 (en) 2007-08-01
JP2006505490A (en) 2006-02-16
CN1646534A (en) 2005-07-27
CA2476279A1 (en) 2003-08-21
MXPA04007876A (en) 2005-06-20

Similar Documents

Publication Publication Date Title
WO2003068162A3 (en) Modified fluorinated nucleoside analogues
WO2002048165A3 (en) Antiviral agents for treatment of flaviviridae infections
WO2004013300A3 (en) Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
EA200200208A1 (en) SYNERGY COMPOSITION
HK1148470A1 (en) Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
WO2004050030A3 (en) Anti-sickling agents
PL367682A1 (en) Dolastatin 10 derivatives
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
ES2587564T1 (en) Antiviral agent
NO2013019I2 (en) Aliskiren or a pharmaceutically acceptable salt thereof, and hydrochlorothiazide or a pharmaceutically acceptable salt thereof.
PL353785A1 (en) Method of treating or inhibiting neurophylic chemotaxis by administering the mek inhibitor
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
BR0212924A (en) Glycogen synthase kinase-3 (gsk-3) inhibitors for the treatment of glaucoma
BRPI0307351B8 (en) compound, pharmaceutical composition, use of a compound, and, process for preparing a compound
AP2005003213A0 (en) 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
BRPI0411365A (en) aminopyridine derivatives
LV12496A (en) Novel guanidine mimics as factor xa inhibitors
MXPA02011691A (en) Methods and compositions for treating flaviviruses and pestiviruses.
BR0315897A (en) anti-infectious agents
WO2006023704A3 (en) Lonidamine analogues and their use in male contraception and cancer treatment
MXPA03008623A (en) Pharmaceutical combinations for the treatment of cancer.
AU2003291885A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
BG106366A (en) Moxifloxacin formulation containing common salt
ES2189968T3 (en) Amidinophenyl-pyrrolidines, -pyrrolines, e -isoxazolidines and derivatives thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007876

Country of ref document: MX

Ref document number: 2003567347

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020047012661

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2476279

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 534811

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003217402

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2589/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003713447

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038083728

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003713447

Country of ref document: EP